The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | MAIA & TOURMALINE-MM3: updates in newly diagnosed multiple myeloma
In this interview, Noopur Raje, MD, of Massachusetts General Hospital, Boston, MA, discusses the Phase III MAIA study (NCT02252172) that aims to further establish the role of daratumumab in the treatment of transplant-ineligible newly diagnosed multiple myeloma (NDMM). Dr Raje also discusses her views on the TOURMALINE-MM3 trial (NCT02181413), showing that maintenance therapy with ixazomib, an oral proteasome inhibitor, was found to significantly prolong progression-free survival following autologous stem cell transplantation in NDMM.
